Document is current
Any future updates will be listed below
-
Authors
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04665921 at ClinicalTrials.govnct05259696 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy
https://doi.org/10.1136/jitc-2025-012391
nct05240131 at ClinicalTrials.govDocuments that mention this clinical trial
Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
https://doi.org/10.1136/jitc-2023-007805
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy
https://doi.org/10.1136/jitc-2025-012391
772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)
https://doi.org/10.1136/jitc-2022-sitc2022.0772
Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy
https://doi.org/10.1136/jitc-2024-009404
758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors
https://doi.org/10.1136/jitc-2024-sitc2024.0758
nct04665921 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy
https://doi.org/10.1136/jitc-2025-012391
nct05259696 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy
https://doi.org/10.1136/jitc-2025-012391
nct05240131 at ClinicalTrials.govDocuments that mention this clinical trial
Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
https://doi.org/10.1136/jitc-2023-007805
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy
https://doi.org/10.1136/jitc-2025-012391
772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)
https://doi.org/10.1136/jitc-2022-sitc2022.0772
Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy
https://doi.org/10.1136/jitc-2024-009404
758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors
https://doi.org/10.1136/jitc-2024-sitc2024.0758
Documents that mention this clinical trial
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy
https://doi.org/10.1136/jitc-2025-012391
-
Funding
Funding for this research was provided by:
Porto Comprehensive Cancer Center Raquel Seruca (n.a.)
CIHR (n.a.)
Mizutani Foundation for Glycoscience (250007)
Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada (n.a.)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_184720/1)
Canadian Glycomics Network (n.a.)
Portuguese Society of Digestive Endoscopy (n.a.)
- License Information
